BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer

Roxana Moslehi, William Chu, Beth Karlan, David Fishman, Harvey Risch, Abbie Fields, David Smotkin, Yehuda Ben-David, Jacalyn Rosenblatt, Donna Russo, Peter Schwartz, Nadine Tung, Ellen Warner, Barry Rosen, Jan Friedman, Jean Sébastien Brunet, Steven A. Narod

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Ovarian cancer is a component of the autosomal-dominant hereditary breast-ovarian cancer syndrome and may be due to a mutation in either the BRCA1 or BRCA2 genes. Two mutations in BRCA1 (185delAG and 5382insC) and one mutation in BRCA2 (6174delT) are common in the Ashkenazi Jewish population. One of these three mutations is present in ~2% of the Jewish population. Each mutation is associated with an increased risk of ovarian cancer, and it is expected that a significant proportion of Jewish women with ovarian cancer will carry one of these mutations. To estimate the proportion of ovarian cancers attributable to founding mutations in BRCA1 and BRCA2 in the Jewish population and the familial cancer risks associated with each, we interviewed 213 Jewish women with ovarian cancer at 11 medical centers in North America and Israel and offered these women genetic testing for the three founder mutations. To establish the presence of nonfounder mutations in this population, we also completed the protein-truncation test on exon 11 of BRCA1 and exons 10 and 11 of BRCA2. We obtained a detailed family history on all women we studied who had cancer and on a control population of 386 Ashkenazi Jewish women without ovarian or breast cancer. A founder mutation was present in 4.1.3% of the women we studied. The cumulative incidence of ovarian cancer to age 75 years was found to be 6.3% for female first-degree relatives of the patients with ovarian cancer, compared with 2.0% for the female relatives of healthy controls (relative risk 3.2; 95% CI 1.5-6.8; P = .002). The relative risk to age 75 years for breast cancer among the female first-degree relatives was 2.0 (95% CI 1.4-3.0; P = .0001). Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.

Original languageEnglish (US)
Pages (from-to)1259-1272
Number of pages14
JournalAmerican Journal of Human Genetics
Volume66
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Ovarian Neoplasms
Mutation
Population
Breast Neoplasms
Hereditary Breast and Ovarian Cancer Syndrome
Exons
BRCA2 Gene
BRCA1 Gene
Genetic Testing
Israel
North America
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., ... Narod, S. A. (2000). BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. American Journal of Human Genetics, 66(4), 1259-1272. https://doi.org/10.1086/302853

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. / Moslehi, Roxana; Chu, William; Karlan, Beth; Fishman, David; Risch, Harvey; Fields, Abbie; Smotkin, David; Ben-David, Yehuda; Rosenblatt, Jacalyn; Russo, Donna; Schwartz, Peter; Tung, Nadine; Warner, Ellen; Rosen, Barry; Friedman, Jan; Brunet, Jean Sébastien; Narod, Steven A.

In: American Journal of Human Genetics, Vol. 66, No. 4, 2000, p. 1259-1272.

Research output: Contribution to journalArticle

Moslehi, R, Chu, W, Karlan, B, Fishman, D, Risch, H, Fields, A, Smotkin, D, Ben-David, Y, Rosenblatt, J, Russo, D, Schwartz, P, Tung, N, Warner, E, Rosen, B, Friedman, J, Brunet, JS & Narod, SA 2000, 'BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer', American Journal of Human Genetics, vol. 66, no. 4, pp. 1259-1272. https://doi.org/10.1086/302853
Moslehi, Roxana ; Chu, William ; Karlan, Beth ; Fishman, David ; Risch, Harvey ; Fields, Abbie ; Smotkin, David ; Ben-David, Yehuda ; Rosenblatt, Jacalyn ; Russo, Donna ; Schwartz, Peter ; Tung, Nadine ; Warner, Ellen ; Rosen, Barry ; Friedman, Jan ; Brunet, Jean Sébastien ; Narod, Steven A. / BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. In: American Journal of Human Genetics. 2000 ; Vol. 66, No. 4. pp. 1259-1272.
@article{0d2417bf5c974a6ba11b2dac163c300d,
title = "BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer",
abstract = "Ovarian cancer is a component of the autosomal-dominant hereditary breast-ovarian cancer syndrome and may be due to a mutation in either the BRCA1 or BRCA2 genes. Two mutations in BRCA1 (185delAG and 5382insC) and one mutation in BRCA2 (6174delT) are common in the Ashkenazi Jewish population. One of these three mutations is present in ~2{\%} of the Jewish population. Each mutation is associated with an increased risk of ovarian cancer, and it is expected that a significant proportion of Jewish women with ovarian cancer will carry one of these mutations. To estimate the proportion of ovarian cancers attributable to founding mutations in BRCA1 and BRCA2 in the Jewish population and the familial cancer risks associated with each, we interviewed 213 Jewish women with ovarian cancer at 11 medical centers in North America and Israel and offered these women genetic testing for the three founder mutations. To establish the presence of nonfounder mutations in this population, we also completed the protein-truncation test on exon 11 of BRCA1 and exons 10 and 11 of BRCA2. We obtained a detailed family history on all women we studied who had cancer and on a control population of 386 Ashkenazi Jewish women without ovarian or breast cancer. A founder mutation was present in 4.1.3{\%} of the women we studied. The cumulative incidence of ovarian cancer to age 75 years was found to be 6.3{\%} for female first-degree relatives of the patients with ovarian cancer, compared with 2.0{\%} for the female relatives of healthy controls (relative risk 3.2; 95{\%} CI 1.5-6.8; P = .002). The relative risk to age 75 years for breast cancer among the female first-degree relatives was 2.0 (95{\%} CI 1.4-3.0; P = .0001). Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.",
author = "Roxana Moslehi and William Chu and Beth Karlan and David Fishman and Harvey Risch and Abbie Fields and David Smotkin and Yehuda Ben-David and Jacalyn Rosenblatt and Donna Russo and Peter Schwartz and Nadine Tung and Ellen Warner and Barry Rosen and Jan Friedman and Brunet, {Jean S{\'e}bastien} and Narod, {Steven A.}",
year = "2000",
doi = "10.1086/302853",
language = "English (US)",
volume = "66",
pages = "1259--1272",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer

AU - Moslehi, Roxana

AU - Chu, William

AU - Karlan, Beth

AU - Fishman, David

AU - Risch, Harvey

AU - Fields, Abbie

AU - Smotkin, David

AU - Ben-David, Yehuda

AU - Rosenblatt, Jacalyn

AU - Russo, Donna

AU - Schwartz, Peter

AU - Tung, Nadine

AU - Warner, Ellen

AU - Rosen, Barry

AU - Friedman, Jan

AU - Brunet, Jean Sébastien

AU - Narod, Steven A.

PY - 2000

Y1 - 2000

N2 - Ovarian cancer is a component of the autosomal-dominant hereditary breast-ovarian cancer syndrome and may be due to a mutation in either the BRCA1 or BRCA2 genes. Two mutations in BRCA1 (185delAG and 5382insC) and one mutation in BRCA2 (6174delT) are common in the Ashkenazi Jewish population. One of these three mutations is present in ~2% of the Jewish population. Each mutation is associated with an increased risk of ovarian cancer, and it is expected that a significant proportion of Jewish women with ovarian cancer will carry one of these mutations. To estimate the proportion of ovarian cancers attributable to founding mutations in BRCA1 and BRCA2 in the Jewish population and the familial cancer risks associated with each, we interviewed 213 Jewish women with ovarian cancer at 11 medical centers in North America and Israel and offered these women genetic testing for the three founder mutations. To establish the presence of nonfounder mutations in this population, we also completed the protein-truncation test on exon 11 of BRCA1 and exons 10 and 11 of BRCA2. We obtained a detailed family history on all women we studied who had cancer and on a control population of 386 Ashkenazi Jewish women without ovarian or breast cancer. A founder mutation was present in 4.1.3% of the women we studied. The cumulative incidence of ovarian cancer to age 75 years was found to be 6.3% for female first-degree relatives of the patients with ovarian cancer, compared with 2.0% for the female relatives of healthy controls (relative risk 3.2; 95% CI 1.5-6.8; P = .002). The relative risk to age 75 years for breast cancer among the female first-degree relatives was 2.0 (95% CI 1.4-3.0; P = .0001). Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.

AB - Ovarian cancer is a component of the autosomal-dominant hereditary breast-ovarian cancer syndrome and may be due to a mutation in either the BRCA1 or BRCA2 genes. Two mutations in BRCA1 (185delAG and 5382insC) and one mutation in BRCA2 (6174delT) are common in the Ashkenazi Jewish population. One of these three mutations is present in ~2% of the Jewish population. Each mutation is associated with an increased risk of ovarian cancer, and it is expected that a significant proportion of Jewish women with ovarian cancer will carry one of these mutations. To estimate the proportion of ovarian cancers attributable to founding mutations in BRCA1 and BRCA2 in the Jewish population and the familial cancer risks associated with each, we interviewed 213 Jewish women with ovarian cancer at 11 medical centers in North America and Israel and offered these women genetic testing for the three founder mutations. To establish the presence of nonfounder mutations in this population, we also completed the protein-truncation test on exon 11 of BRCA1 and exons 10 and 11 of BRCA2. We obtained a detailed family history on all women we studied who had cancer and on a control population of 386 Ashkenazi Jewish women without ovarian or breast cancer. A founder mutation was present in 4.1.3% of the women we studied. The cumulative incidence of ovarian cancer to age 75 years was found to be 6.3% for female first-degree relatives of the patients with ovarian cancer, compared with 2.0% for the female relatives of healthy controls (relative risk 3.2; 95% CI 1.5-6.8; P = .002). The relative risk to age 75 years for breast cancer among the female first-degree relatives was 2.0 (95% CI 1.4-3.0; P = .0001). Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.

UR - http://www.scopus.com/inward/record.url?scp=0033927850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033927850&partnerID=8YFLogxK

U2 - 10.1086/302853

DO - 10.1086/302853

M3 - Article

C2 - 10739756

AN - SCOPUS:0033927850

VL - 66

SP - 1259

EP - 1272

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 4

ER -